ライフサイエンスコーパス: peginterferon

1 ) were less common with sofosbuvir than with peginterferon.

2 were less frequent with sofosbuvir than with peginterferon.

3 was suspected to be a direct complication of peginterferon.

4 ed and as related or not to complications of peginterferon.

5 atients with an adequate initial response to peginterferon.

6 score and baseline HCV RNA level, to receive peginterferon 1.5 mug/kg per week with weight-based riba

7 ebo (2:2:1) for 12 weeks in combination with peginterferon (180 mug per week) and ribavirin (1000-120

8 domized to 12 weeks of TVR (750 mg q8h) plus peginterferon (180 mug/week) and ribavirin (1,000-1,200

9 aprevir (750 mg every 8 h), placebo plus PR (peginterferon, 180 mug, once weekly and ribavirin, 400 m

10 hronic hepatitis B respond to treatment with peginterferon alfa (PEG-IFN).

11 eive simeprevir (150 mg once daily, orally), peginterferon alfa 2a (180 mug once weekly, subcutaneous

12 Simeprevir once daily with peginterferon alfa 2a and ribavirin shortens therapy in

13 3/4A protease inhibitor versus placebo, plus peginterferon alfa 2a or 2b plus ribavirin was assessed

14 lacebo group) for 12 weeks, followed by just peginterferon alfa 2a or 2b plus ribavirin.

15 evir group) or placebo (once daily, orally), peginterferon alfa 2a or 2b, plus ribavirin (placebo gro

16 Addition of simeprevir to either peginterferon alfa 2a or peginterferon alfa 2b plus riba

17 2a plus ribavirin for 12 weeks, followed by peginterferon alfa 2a plus ribavirin (placebo group).

18 2a plus ribavirin for 12 weeks, followed by peginterferon alfa 2a plus ribavirin (simeprevir group),

19 simeprevir (150 mg once daily, orally) plus peginterferon alfa 2a plus ribavirin for 12 weeks, follo

20 n (simeprevir group), or placebo orally plus peginterferon alfa 2a plus ribavirin for 12 weeks, follo

21 ly, oral HCV NS3/4A protease inhibitor, plus peginterferon alfa 2a plus ribavirin were assessed in tr

22 g the adverse event profiles associated with peginterferon alfa 2a plus ribavirin.

23 a 2a, and ribavirin was superior to placebo, peginterferon alfa 2a, and ribavirin (SVR12 in 210 [80%]

24 Treatment with simeprevir, peginterferon alfa 2a, and ribavirin was superior to pla

25 00 mg/day) (n = 58 in the final analysis) or peginterferon alfa 2b (1.5 mcg/kg/wk), ribavirin (1000-1

26 imeprevir to either peginterferon alfa 2a or peginterferon alfa 2b plus ribavirin improved SVR in tre

27 ups, and were typical of those expected from peginterferon alfa and ribavirin therapy.

28 Peginterferon alfa is the only recommended therapy, but

29 ing the known adverse events associated with peginterferon alfa plus ribavirin.

30 rant of, or ineligible for and intolerant of peginterferon alfa plus ribavirin.

31 treatment-naive; previous non-responders to peginterferon alfa plus ribavirin; or medically ineligib

32 249 [97%] vs 132 [99%]), irrespective of the peginterferon alfa used.

33 Treatment guidelines recommend 1 year of peginterferon alfa, which is effective in 25-30% of pati

34 then 750 mg every 8 hours) for 12 weeks and peginterferon alfa-2a (180 microg per week) and ribaviri

35 f 0.015 mg/kg (0.5 mg maximum) for 48 weeks; peginterferon alfa-2a (180 ug/1.73m(2) subcutaneously) o

36 otent second-generation protease inhibitor), peginterferon alfa-2a (40 KD), and ribavirin in these pa

37 in which patients received mericitabine plus peginterferon alfa-2a (40KD)/ribavirin were analyzed by

38 aily for 8 weeks followed by the addition of peginterferon alfa-2a 180 ug/week to entecavir for an ad

39 daily) alone (Group A, 11 patients) or with peginterferon alfa-2a and ribavirin (Group B, 10 patient

40 group A, 11 patients) or in combination with peginterferon alfa-2a and ribavirin (group B, 10 patient

41 were randomized 2:1:1 to receive 48 weeks of peginterferon alfa-2a and ribavirin (PegIFN/RBV) in comb

42 ty of 2 weeks therapy with telaprevir alone, peginterferon alfa-2a and ribavirin (PR), or all 3 drugs

43 or 12 weeks; patients were then treated with peginterferon alfa-2a and ribavirin alone for 12 weeks i

44 bavirin for 12 weeks followed by 36 weeks of peginterferon alfa-2a and ribavirin alone.

45 previous null responders with simeprevir and peginterferon alfa-2a and ribavirin and telaprevir and p

46 of sustained virologic response (SVR) after peginterferon alfa-2a and ribavirin combination therapy

47 : a group receiving telaprevir combined with peginterferon alfa-2a and ribavirin for 12 weeks (T12PR

48 vir placebo (once a day) in combination with peginterferon alfa-2a and ribavirin for 12 weeks followe

49 mg twice daily or 750 mg every 8 hours plus peginterferon alfa-2a and ribavirin for 12 weeks; patien

50 group, receiving telaprevir for 24 weeks and peginterferon alfa-2a and ribavirin for 48 weeks (at the

51 ts to the PR48 (or control) group, receiving peginterferon alfa-2a and ribavirin for 48 weeks (at the

52 , all 10 (100%) who received sofosbuvir plus peginterferon alfa-2a and ribavirin for 8 weeks had a su

53 monotherapy for 12 weeks or sofosbuvir plus peginterferon alfa-2a and ribavirin for 8 weeks.

54 ribavirin was non-inferior to telaprevir and peginterferon alfa-2a and ribavirin for SVR12 (54% [203/

55 istered a 12-week regimen of sofosbuvir plus peginterferon alfa-2a and ribavirin in 327 patients with

56 Peginterferon alfa-2a and ribavirin therapy provides goo

57 ron alfa-2a and ribavirin and telaprevir and peginterferon alfa-2a and ribavirin treatment, respectiv

58 nders during at least one previous course of peginterferon alfa-2a and ribavirin treatment.

59 Simeprevir and peginterferon alfa-2a and ribavirin was non-inferior to

60 Simeprevir once a day with peginterferon alfa-2a and ribavirin was well tolerated i

61 , and 900 mg every 12 hours) or placebo plus peginterferon alfa-2a and ribavirin, followed by peginte

62 atment with daclatasvir, in combination with peginterferon alfa-2a and ribavirin, is a well tolerated

63 nterferon alfa-2a and ribavirin, followed by peginterferon alfa-2a and ribavirin.

64 who were given placebo received 48 weeks of peginterferon alfa-2a and ribavirin.

65 d SVR48 after treatment intensification with peginterferon alfa-2a and ribavirin.

66 t-acting antiviral agents were combined with peginterferon alfa-2a and ribavirin.

67 , or 24 weeks of placebo, each combined with peginterferon alfa-2a and ribavirin.

68 cacy to telaprevir, each in combination with peginterferon alfa-2a and ribavirin.

69 elaprevir at a dose of 750 mg every 8 hours, peginterferon alfa-2a at a dose of 180 mug per week, and

70 Peginterferon alfa-2a could be an effective therapy for

71 Additional groups included 360 mug/wk peginterferon alfa-2a for 12 weeks then 180 mug/wk pegin

72 o the T24P24 group, receiving telaprevir and peginterferon alfa-2a for 24 weeks (at the same doses as

73 erferon alfa-2a for 12 weeks then 180 mug/wk peginterferon alfa-2a for 36 weeks plus 1200 mg/day riba

74 Three of these groups also received peginterferon alfa-2a for 4, 8, or 12 weeks.

75 Whether prolonged therapy with peginterferon alfa-2a for 96 weeks and combination thera

76 group and in 20 (33%) of 61 patients in the peginterferon alfa-2a plus placebo group (odds ratio 1.8

77 erferon alfa-2a plus TDF group and 25 in the peginterferon alfa-2a plus placebo group).

78 rferon alfa-2a plus TDF group and 485 in the peginterferon alfa-2a plus placebo group).

79 nterferon alfa-2a plus TDF and 61 to receive peginterferon alfa-2a plus placebo, including 48 (40%) p

80 ve sofosbuvir plus ribavirin for 12 weeks or peginterferon alfa-2a plus ribavirin for 24 weeks.

81 , underwent 48-week combination therapy with peginterferon alfa-2a plus ribavirin.

82 We evaluated intensified therapy with peginterferon alfa-2a plus ribavirin.

83 gned 59 HDV RNA-positive patients to receive peginterferon alfa-2a plus TDF and 61 to receive peginte

84 hosis to the two treatment groups (23 in the peginterferon alfa-2a plus TDF group and 25 in the pegin

85 We recorded 944 adverse events (459 in the peginterferon alfa-2a plus TDF group and 485 in the pegi

86 s achieved in 28 (48%) of 59 patients in the peginterferon alfa-2a plus TDF group and in 20 (33%) of

87 erences among the 4 groups or between pooled peginterferon alfa-2a regimens (A + B vs C + D: odds rat

88 ck randomisation (1:1) to receive 180 mug of peginterferon alfa-2a weekly plus either TDF (300 mg onc

89 The combination of danoprevir, peginterferon alfa-2a, and ribavirin leads to high rates

90 The strength of peginterferon alfa-2a-induced IFIG response significantl

91 subset, a potential prognostic indicator in peginterferon alfa-2a-treated patients with HIV infectio

92 -associated Kaposi sarcoma were treated with peginterferon alfa-2a.

93 ed volunteers were treated for 12 weeks with peginterferon alfa-2a.

94 tional study enrolling patients treated with peginterferon alfa-2a/ribavirin (PEG/RBV) with or withou

95 revir, an HCV NS3-4A protease inhibitor) and peginterferon alfa-2a/ribavirin (PR) in patients with ge

96 405 patients treated with mericitabine plus peginterferon alfa-2a/ribavirin in PROPEL and JUMP-C, vi

97 (PR48), combined with a total of 48 weeks of peginterferon alfa-2a/ribavirin.

98 Boceprevir (BOC) added to peginterferon alfa-2b (PegIFN) and ribavirin (RBV) signi

99 infection were randomly assigned to receive peginterferon alfa-2b 1.5 mug/kg plus ribavirin 800-1400

100 00-1400 mg daily for 48 weeks (PR48; n=104); peginterferon alfa-2b and ribavirin daily for 4 weeks, f

101 In all three groups, peginterferon alfa-2b and ribavirin were administered fo

102 virus oral protease inhibitor, when added to peginterferon alfa-2b and ribavirin.

103 and ribavirin daily for 4 weeks, followed by peginterferon alfa-2b, ribavirin, and boceprevir 800 mg

104 4; n=103) or 44 weeks (PR4/PRB44; n=103); or peginterferon alfa-2b, ribavirin, and boceprevir three t

105 not had a sustained virologic response after peginterferon alfa-ribavirin therapy to one of four trea

106 c failure with telaprevir or boceprevir plus peginterferon alfa-ribavirin).

107 Pegylated interferon (peginterferon) alfa 2a or 2b plus ribavirin regimens wer

108 evir and telaprevir to pegylated interferon (peginterferon) alfa plus ribavirin has improved sustaine

109 combination of boceprevir or telaprevir with peginterferon-alfa and ribavirin for the treatment of pa

110 Combined with peginterferon-alfa plus ribavirin they offer genotype-1

111 virin for 24 weeks (n = 199); or sofosbuvir, peginterferon-alfa, and ribavirin for 12 weeks (n = 197)

112 f sofosbuvir and ribavirin, with and without peginterferon-alfa, in treatment-experienced patients wi

113 Peginterferon alpha and RBV can significantly affect lip

114 Retreatment with peginterferon alpha and ribavirin (PR) offers a limited

115 ls (RCTs) show that triple therapy (TT) with peginterferon alpha, ribavirin, and boceprevir (BOC) or

116 corded coffee intake before retreatment with peginterferon alpha-2a (180 mug/wk) and ribavirin (1000-

117 prove virologic response rates compared with peginterferon alpha-2a plus ribavirin alone.

118 resistance to receive either standard care (peginterferon alpha-2a plus ribavirin for 48 weeks, n =

119 ioglitazone before and during treatment with peginterferon alpha-2a plus ribavirin improved several i

120 pha-2b-ribavirin, and 47% in genotype 1 with peginterferon alpha-2a-ribavirin.

121 nt, the decrease from baseline to Week 12 of peginterferon alpha-2a/ribavirin treatment in mean log(1

122 d 1:1 to 20 weeks of additional therapy with peginterferon alpha-2b and ribavirin (double therapy) or

123 68 HCV patients receiving antiviral therapy (peginterferon alpha-2b and ribavirin) we performed a lon

124 After 4 weeks of lead-in therapy with peginterferon alpha-2b and ribavirin, 101 patients (48%)

125 ribavirin (double therapy) or to 24 weeks of peginterferon alpha-2b, ribavirin, and boceprevir (tripl

126 fection, estimated at 53% in genotype 1 with peginterferon alpha-2b-ribavirin, and 47% in genotype 1

127 The effect of peginterferon alpha/ribavirin (PEG-IFN/RBV) and hepatiti

128 n associated with poor virologic response to peginterferon alpha/ribavirin (PR) in chronic hepatitis

129 th polyethylene glycol decorated interferon (peginterferon) alpha and ribavirin (PR) is associated wi

130 HCV antiviral treatment (peginterferon-alpha + ribavirin) has been shown to be co

131 onic hepatitis C (CHC) who were treated with peginterferon-alpha and ribavirin.

132 ron were prospectively randomized to receive peginterferon-alpha-2a (180 mug/d) plus either RBV stand

133 any one of the new DAAs is given along with peginterferon-alpha/ribavirin, clinical trials exploring

134 Telaprevir (TVR) plus peginterferon-alpha2a (PEG-IFN-alpha2a) and ribavirin su

135 and safety of the combination of simeprevir, peginterferon-alpha2a (PegIFN), and ribavirin (RBV) in p

136 virus (HCV) genotype 2/3 infection receiving peginterferon-alpha2a and lower, conventional 800 mg dai

137 Prolonged low-dose peginterferon-alpha2a therapy and beta-blockers do not r

138 The peginterferon and entecavir monotherapy groups also diff

139 8 weeks of entecavir followed by combination peginterferon and entecavir therapy for 40 weeks had lim

140 When utilized with peginterferon and RBV for 12 weeks in treatment-naive pa

141 sis who did not respond to a prior course of peginterferon and ribavirin (44.3% relapsers or patients

142 fully treated with a protease inhibitor with peginterferon and ribavirin (50% could have compensated

143 ts (61%) had not responded to treatment with peginterferon and ribavirin (null responders), and 32 (3

144 he efficacy and tolerability of MK-5172 with peginterferon and ribavirin (PR) in treatment-naive pati

145 d the efficacy and safety of sofosbuvir plus peginterferon and ribavirin (SOF+Peg-IFN+RBV) administer

146 ribavirin (triple therapy) after 4 weeks of peginterferon and ribavirin (total treatment duration, 2

147 d -experienced patients, in conjunction with peginterferon and ribavirin (triple therapy), in phase 3

148 who also had better on-treatment response to peginterferon and ribavirin during follow up.

149 s (cohort B), or 12 weeks of sofosbuvir plus peginterferon and ribavirin followed by 12 weeks of eith

150 Patients (n = 687) received 4 weeks of peginterferon and ribavirin followed by 24 or 44 weeks o

151 Patients received sofosbuvir 400 mg plus peginterferon and ribavirin for 12 weeks (cohort A) or f

152 se 2 and 3 trials, of sofosbuvir 400 mg plus peginterferon and ribavirin for 12 weeks in treatment-na

153 ) received open-label sofosbuvir 400 mg plus peginterferon and ribavirin for 12 weeks.

154 D-2] trial) received either a combination of peginterferon and ribavirin for 48 weeks or boceprevir,

155 0-1200 mg daily), after which they continued peginterferon and ribavirin for an additional 12 weeks o

156 Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C viru

157 Finally, the continued role of peginterferon and ribavirin in future therapies will be

158 the effectiveness of the protease inhibitors peginterferon and ribavirin in treatment-experienced pat

159 with HCV genotype 1 infections, therapy with peginterferon and ribavirin is associated with decreases

160 who have not had a response to therapy with peginterferon and ribavirin may benefit from the additio

161 a rapid virologic response after 4 weeks of peginterferon and ribavirin therapy are likely to achiev

162 atients with advanced hepatitis C who failed peginterferon and ribavirin therapy, the rate of liver-r

163 among patients who had not cleared virus on peginterferon and ribavirin therapy.

164 naemia and neutropenia--were associated with peginterferon and ribavirin treatment.

165 roximately one-half the rate of whites after peginterferon and ribavirin treatment.

166 ype 2 or 3 infection for whom treatment with peginterferon and ribavirin was not an option, 12 or 16

167 is review summarizes the pharmacokinetics of peginterferon and ribavirin with a particular emphasis o

168 The combination of peginterferon and ribavirin with telaprevir or boceprevi

169 and cirrhosis respond to the combination of peginterferon and ribavirin with telaprevir or boceprevi

170 ost patients had failed prior treatment with peginterferon and ribavirin without (46%) or with telapr

171 HCV RNA after >/=12 weeks of treatment with peginterferon and ribavirin).

172 onse of patients with chronic hepatitis C to peginterferon and ribavirin, little is known regarding i

173 or partial response to previous therapy with peginterferon and ribavirin, received daily doses of 150

174 ined virologic response after treatment with peginterferon and ribavirin, with or without a protease

175 thout cirrhosis who received telaprevir with peginterferon and ribavirin.

176 f boceprevir (800 mg, 3 times each day) plus peginterferon and ribavirin.

177 --were consistent with those associated with peginterferon and ribavirin.

178 r had not responded to previous therapy with peginterferon and ribavirin.

179 tients with chronic hepatitis C treated with peginterferon and ribavirin.

180 , without cirrhosis, previously treated with peginterferon and ribavirin.

181 reatment compared with pegylated interferon (peginterferon) and ribavirin alone (56% vs 34% overall;

182 mbination with pegylated interferon alfa-2a (peginterferon) and ribavirin in non-cirrhotic treatment-

183 ously not responded to pegylated interferon (peginterferon) and ribavirin or were treatment naive.

184 oceprevir plus pegylated interferon alfa-2b (peginterferon) and ribavirin, which increases rates of S

185 B polymorphism rs12979860, dose reduction of peginterferon, and other covariates, odds ratios for dri

186 f response to the combination of telaprevir, peginterferon, and ribavirin (group 1: 96.6%; 95% confid

187 on and ribavirin for 48 weeks or boceprevir, peginterferon, and ribavirin (triple therapy) after 4 we

188 tis C virus (HCV) infection with boceprevir, peginterferon, and ribavirin can lead to anemia, which h

189 th cirrhosis, the combination of sofosbuvir, peginterferon, and ribavirin for 12 weeks produces high

190 ely, and 94% for those receiving sofosbuvir, peginterferon, and ribavirin for 12 weeks.

191 hepatitis C virus (HCV) protease inhibitor, peginterferon, and ribavirin is the standard of care for

192 vely, and 93% in those receiving sofosbuvir, peginterferon, and ribavirin.

193 similar population treated with telaprevir, peginterferon, and ribavirin.

194 ratified by site, to placebo or subcutaneous peginterferon beta-1a 125 mug once every 2 weeks or ever

195 We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the

196 After 48 weeks, peginterferon beta-1a significantly reduced relapse rate

197 e most common adverse events associated with peginterferon beta-1a were injection site reactions, inf

198 Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment

199 intenance therapy with pegylated interferon (peginterferon) does not reduce liver disease progression

200 re randomly assigned (500 to placebo, 512 to peginterferon every 2 weeks, 500 to peginterferon every

201 ts taking placebo, 481 (94%) patients taking peginterferon every 2 weeks, and 472 (94%) patients taki

202 every 2 weeks, and 472 (94%) patients taking peginterferon every 4 weeks reported adverse events incl

203 , 512 to peginterferon every 2 weeks, 500 to peginterferon every 4 weeks); 1332 (88%) patients comple

204 The peginterferon-experienced patients had a lower HCC incid

205 cohort analysis (P = .009 for comparison of peginterferon-experienced vs nucleotide analogue-treated

206 Conclusion: The combination of entecavir and peginterferon for up to 48 weeks rarely led to loss of H

207 y and efficacy of therapy with entecavir and peginterferon in a group of children in the immune-toler

208 efficacy of the combination of entecavir and peginterferon in adults in the IT phase of chronic HBV i

209 Long-term maintenance peginterferon in patients with advanced chronic hepatiti

210 ith SOF and ribavirin (RBV), with or without peginterferon, including 54% with cirrhosis and 49% who

211 HCV) genotype 2 or 3 for whom treatment with peginterferon is not an option, or who have not had a re

212 cohort (n = 64) of CHB patients treated with peginterferon/nucleotide analogue combination therapy.

213 o 48 weeks in one of the following arms: (1) peginterferon (PEG-IFN) alfa-2b at 1.5 microg/kg/week wi

214 ely than whites to respond to treatment with peginterferon (PEG-IFN) plus ribavirin (RBV).

215 face antigen (HBsAg) may predict response to peginterferon (PEG-IFN) therapy in chronic hepatitis B (

216 sferase (ALT) flares occur frequently during peginterferon (PEG-IFN) therapy.

217 Peginterferon (PEG-IFN) treatment of hepatitis B e antig

218 s with genotype 1 HCV infection who received peginterferon (PEG-IN) alfa-2a plus ribavirin therapy fo

219 imeprevir was recently approved for use with peginterferon (PEGINF) and ribavirin (RBV) in patients w

220 ined virological response (SVR) rates during peginterferon plus ribavirin (RBV) therapy.

221 Peginterferon plus ribavirin achieves sustained virologi

222 fection, the main genotype worldwide, is now peginterferon plus ribavirin and a protease inhibitor.

223 predictor of improved virologic response to peginterferon plus ribavirin in patients with hepatitis

224 had history of prior treatment failure with peginterferon plus ribavirin therapy.

225 vious null response to pegylated interferon (peginterferon) plus ribavirin (PR-null responders).

226 red with 84% of 19 patients treated with SOF/peginterferon/RBV.

227 For genotype 1, we compare: (1) peginterferon + ribavirin + telaprevir for 12 weeks, fol

228 ith genotype 2, 24 weeks for genotype 3; (3) peginterferon + ribavirin as initial treatment, 24 weeks

229 eks, followed by 12 or 24 weeks treatment of peginterferon + ribavirin dependent on HCV RNA level at

230 fective as second-phase treatments following peginterferon + ribavirin initial treatment for genotype

231 or patients with cirrhosis; (5) sofosbuvir + peginterferon + ribavirin, 12 weeks for patients with or

232 s 2 and 3, treatment strategies include: (1) peginterferon + ribavirin, 24 weeks for treatment-naive

233 HCV) genotype 1 includes triple therapy with peginterferon, ribavirin, and a protease inhibitor.

234 r management of anemia in patients receiving peginterferon, ribavirin, and boceprevir for HCV infecti

235 We compared a regimen of peginterferon, ribavirin, and sofosbuvir with a regimen

236 iral relapse rate, than a 12-week regimen of peginterferon, ribavirin, and sofosbuvir.

237 avirin for 12 weeks, followed by 36 weeks of peginterferon-ribavirin (PR group).

238 irin for 12 weeks (T12PR group), followed by peginterferon-ribavirin alone for 12 weeks if HCV RNA wa

239 th peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, has shown improved effica

240 th peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, was associated with signi

241 c HCV genotype 1 infection, as compared with peginterferon-ribavirin alone.

242 eiving telaprevir than among those receiving peginterferon-ribavirin alone.

243 Three patients who received boceprevir plus peginterferon-ribavirin and four controls had HIV virolo

244 rrhosis who had previously been treated with peginterferon-ribavirin and had a relapse, a partial res

245 s of sustained virological response (SVR) to peginterferon-ribavirin are low in patients with hepatit

246 Boceprevir in combination with peginterferon-ribavirin could be an important therapeuti

247 ) or telaprevir (TVR) is more effective than peginterferon-ribavirin dual therapy (DT) in the treatme

248 criteria; or a group receiving placebo with peginterferon-ribavirin for 12 weeks, followed by 36 wee

249 r 44 weeks; group 2 received boceprevir plus peginterferon-ribavirin for 24 weeks, and those with a d

250 received treatment previously, a regimen of peginterferon-ribavirin for 24 weeks, with telaprevir fo

251 group 2, a total of 44% of patients received peginterferon-ribavirin for 28 weeks.

252 r 44 weeks; group 2 received boceprevir plus peginterferon-ribavirin for 32 weeks, and patients with

253 feron-ribavirin for 8 weeks and placebo with peginterferon-ribavirin for 4 weeks (T8PR group), follow

254 weeks; and group 3 received boceprevir plus peginterferon-ribavirin for 44 weeks.

255 weeks; and group 3 received boceprevir plus peginterferon-ribavirin for 44 weeks.

256 1 (the control group) received placebo plus peginterferon-ribavirin for 44 weeks; group 2 received b

257 roup 1 (control group) received placebo plus peginterferon-ribavirin for 44 weeks; group 2 received b

258 ime point; a group receiving telaprevir with peginterferon-ribavirin for 8 weeks and placebo with peg

259 CV RNA level at week 8 received placebo plus peginterferon-ribavirin for an additional 12 weeks; and

260 between weeks 8 and 24 received placebo plus peginterferon-ribavirin for an additional 20 weeks; and

261 effect of the combination of boceprevir and peginterferon-ribavirin for retreatment of patients with

262 both the sofosbuvir-ribavirin group and the peginterferon-ribavirin group.

263 enced participants who had been treated with peginterferon-ribavirin had HCV genotype 2 or 3, for a t

264 (T8PR group), followed by 12 or 36 weeks of peginterferon-ribavirin on the basis of the same HCV RNA

265 00-1400 mg per day) for 4 weeks, followed by peginterferon-ribavirin plus either placebo (control gro

266 The addition of boceprevir to peginterferon-ribavirin resulted in significantly higher

267 Peginterferon-ribavirin therapy is the current standard

268 irus (HCV) genotype 1 often need 48 weeks of peginterferon-ribavirin treatment for a sustained virolo

269 pe 1 protease inhibitor, in combination with peginterferon-ribavirin, as compared with peginterferon-

270 Telaprevir with peginterferon-ribavirin, as compared with peginterferon-

271 ition of boceprevir to standard therapy with peginterferon-ribavirin, as compared with standard thera

272 ot have a sustained response to therapy with peginterferon-ribavirin, outcomes after retreatment are

273 ngle-group study of sofosbuvir combined with peginterferon-ribavirin, patients with predominantly gen

274 had received retreatment with telaprevir and peginterferon-ribavirin.

275 per day, for 12 weeks (T12PR12), followed by peginterferon-ribavirin.

276 in patients who were previously treated with peginterferon-ribavirin.

277 mediately (T12/PR48) or following 4 weeks of peginterferon/ribavirin (lead-in T12/PR48), or 12 weeks

278 notype 1 patients with hepatitis C and prior peginterferon/ribavirin (PR) treatment failure.

279 In comparison with peginterferon/ribavirin alone, boceprevir with peginterf

280 (N = 7,163) age >/= 18 years were prescribed peginterferon/ribavirin at the discretion of the treatin

281 Coadministration of pioglitazone with peginterferon/ribavirin improves insulin sensitivity and

282 ginterferon/ribavirin alone, boceprevir with peginterferon/ribavirin significantly improves sustained

283 s C virus (HCV)-infected patients with prior peginterferon/ribavirin treatment failure (including rel

284 ve a sustained virologic response (SVR) with peginterferon/ribavirin would be useful in optimizing tr

285 vel resistance; virologic failure during the peginterferon/ribavirin-treatment phase was associated w

286 chieve undetectable viremia after 4 weeks of peginterferon/ribavirin.

287 s of the HALT-C cohort showed that long-term peginterferon therapy does not reduce the incidence of H

288 ized controlled study of long-term, low-dose peginterferon therapy in patients with advanced chronic

289 entecavir-treated and pegylated interferon (peginterferon)-treated patients.

290 tly suppressed to levels lower than those of peginterferon-treated patients (P < .001).

291 tecavir-treated patients with HCC but not in peginterferon-treated patients (P = .015).

292 Because maintenance peginterferon treatment did not alter liver disease prog

293 Patients with cirrhosis who received peginterferon treatment had a lower risk of HCC than con

294 randomized study of 3.5 years of maintenance peginterferon treatment on liver disease progression amo

295 treated patients; P = .022 for comparison of peginterferon- vs entecavir-treated patients).

296 Treatment by peginterferon was associated with a lower HCC incidence

297 one trial, patients for whom treatment with peginterferon was not an option received oral sofosbuvir

298 Among patients for whom treatment with peginterferon was not an option, the rate of a sustained

299 infection who received either sofosbuvir or peginterferon with ribavirin had nearly identical rates

300 prolonged treatment of HDV with 96 weeks of peginterferon would increase HDV RNA response rates and